Total adverse events between 0 and 16 weeks · predominantly knee osteoarthritis
Antidepressant leads to higher total adverse events between 0 and 16 weeks compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events between 0 and 16 weeks · predominantly knee osteoarthritis
Antidepressant showed no clear difference in serious adverse events between 0 and 16 weeks compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Paina Scale: 0 to 100, 0 is no pain · people with degenerative knee disease (osteoarthritis including degenerative meniscal tears)
1 finding from 1 review
Intervention not reported
Knee functiona Scale: 0 to 100, 100 is best function · people with degenerative knee disease (osteoarthritis including degenerative meniscal tears)
1 finding from 1 review
Intervention not reported
Knee‐specific health‐related quality of lifea Scale: 0 to 100, 100 is best quality of life · people with degenerative knee disease (osteoarthritis including degenerative meniscal tears)
1 finding from 1 review
Intervention not reported
Participant‐reported success Last · people with degenerative knee disease (osteoarthritis including degenerative meniscal tears)
The intervention showed no clear difference in participant‐reported success Last (low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse eventsLast · people with degenerative knee disease (osteoarthritis including degenerative meniscal tears)
The intervention showed no clear difference in serious adverse eventsLast (low certainty).
1 finding from 1 review
Intervention not reported
Total adverse events Last · people with degenerative knee disease (osteoarthritis including degenerative meniscal tears)
The intervention showed no clear difference in total adverse events Last (low certainty).
1 finding from 1 review
Intervention not reported
Knee surgery (replacement or osteotomy)Last · people with degenerative knee disease (osteoarthritis including degenerative meniscal tears)
The intervention showed no clear difference in knee surgery (replacement or osteotomy)Last (low certainty).
1 finding from 1 review
Pain ‐ not reported · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Proportion with 50% or greater decrease in inflammation score from baseline ‐ 32 to 36 hours · acute gout
High‐dose colchicine may leads to higher reduction of inflammation: proportion with 50% or greater decrease… compared with placebo (low certainty).
1 finding from 1 review
Function of target joint ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · acute gout
1 finding from 1 review
Total adverse events · acute gout
High‐dose colchicine may leads to higher total adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · acute gout
1 finding from 1 review
Pain ‐ not reported · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Participant global assessment of treatment success: proportion with 50% or greater decrease in pain score from baseline ‐ 32 to 36 hours · acute gout
High‐dose showed no clear difference in participant global assessment of treatment success: proportion with… compared with low‐dose colchicine (low certainty).
1 finding from 1 review
Reduction of inflammation ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Function of target joint ‐ not measured · acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events · acute gout
1 finding from 1 review